Refractory primary central nervous system lymphoma treated with programmed death-1 monoclonal antibody and Bruton tyrosine kinase inhibitor combined with rituximab: report of 1 case and review of literature
10.3760/cma.j.cn115356-20211123-00270
- VernacularTitle:程序性死亡受体1单抗及布鲁顿酪氨酸激酶抑制剂联合利妥昔单抗治疗难治原发中枢神经系统淋巴瘤1例并文献复习
- Author:
Jia LI
1
;
Yangzhi ZHAO
;
Wei GUO
;
Hongguang ZHAO
;
Le DOU
;
Junna LI
;
Ou BAI
Author Information
1. 吉林大学第一医院血液科，长春 130000
- Keywords:
Central nervous system neoplasms;
Primary central nervous system lymphoma;
Refractory;
Molecular targeted therapy;
Programmed death receptor 1 monoclonal
- From:
Journal of Leukemia & Lymphoma
2022;31(12):734-737
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the effect and safety of rituximab, programmed death 1 (PD-1) monoclonal antibody, and Bruton tyrosine kinase (BTK) inhibitor on elderly refractory primary central nervous system lymphoma (PCNSL).Methods:The clinical data of an elderly patient with refractory PCNSL treated with the combination of rituximab, PD-1 monoclonal antibody and BTK inhibitor in the First Hospital of Jilin University in February 2020 were retrospectively analyzed. The relevant literature was reviewed.Results:The patient had primary central nervous system diffuse large B-cell lymphoma (high-risk group), and the Memorial Sloan Kettering Cancer Center (MSKCC) score was 2 (estimated overall survival time was 7 months). Disease progressed after 1 course of treatment. Complete remission was achieved after the therapy of rituximab, PD-1 monoclonal antibody combined with BTK inhibitor. PD-1 monoclonal antibody maintenance therapy was performed and patient was followed up until November 17, 2021. The patient's condition was stable. The second progression-free survival (PFS) time was 20 months, and the overall survival time was 21 months. The patient well tolerated the new drug treatment, and no adverse reactions of grade 3 or above occurred.Conclusions:The new targeted combination therapy can be used as a treatment option for elderly PCNSL patients, which can further improve the curative effect and significantly improve the prognosis.
